Aegerion Pharma (AEGR) Misses Q2 EPS by 34c
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Aegerion Pharma (NASDAQ: AEGR) reported Q2 EPS of ($0.72), $0.34 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $44.5 million versus the consensus estimate of $35.5 million.
For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AK Steel (AKS) Pares Earlier Gains, Shares Whipsaw
- Allegiance Bancshares, Inc. (ABTX) Reports In-Line Q4 EPS
- Corning (GLW) Tops Q4 EPS by 6c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!